The Nose Knows: A Local Antibody Could Be the Key to Stopping RSV Before It Starts

Most of what we know about immunity to respiratory syncytial virus (RSV) comes from blood tests. Researchers measure antibodies circulating in serum and use those levels to judge whether a vaccine or monoclonal antibody is likely to work. But a new study from The Gambia suggests that looking only at blood may miss half the story — and that antibodies sitting in the nose itself might matter more for stopping infection in the first place.

RSV remains a major global killer of young children, with the overwhelming majority of deaths occurring in low- and middle-income countries. Infants under six months are especially vulnerable. While new tools like long-acting monoclonal antibodies and maternal vaccines have shown real success in preventing severe disease and hospitalization, scientists still don't fully understand why RSV infects people again and again throughout life, or which immune markers best predict whether someone will catch the virus at all — as opposed to just avoiding severe illness once infected.

A Household Study Built for Catching Infections in Real Time

To dig into this, the research team followed 342 people in Gambian households for a full year, testing them weekly with PCR swabs regardless of symptoms, while also collecting blood and nasal samples over time. This kind of intensive, prospective design is unusual — it captures infections that would otherwise go unnoticed, including mild or asymptomatic cases, and it does so in a high-transmission, real-world setting rather than a controlled clinical trial. The researchers then built a statistical model that combined antibody kinetics, patterns of transmission within households, and the reality that PCR tests aren't perfect, to work out which immune markers were most closely linked to staying infection-free.

Mucosal IgA Outperformed Blood-Based Markers

The standout finding involves a specific antibody: IgA targeting the pre-fusion form of the RSV F protein, measured directly in nasal secretions rather than blood. This mucosal IgA was the strongest predictor of protection against infection in the study, with a discriminatory accuracy (AUC) of 0.72 — notably better than serum IgG against the same viral target, which scored 0.66. In practical terms, this means that antibody levels sampled from the nose tracked more closely with who did and didn't get infected than the standard blood-based measure did.

Serum and mucosal antibody levels didn't correlate much with each other — the researchers found only weak associations (correlation coefficients between 0.02 and 0.28), implying that what's happening in the blood and what's happening at the site where the virus actually enters the body are, to a large extent, separate processes. When the team combined both mucosal and serum measurements into a single model, prediction improved further, suggesting the two compartments capture complementary rather than redundant information. Both measures were also linked to how well a person's antibodies could neutralize RSV-A in laboratory tests, reinforcing that they're picking up on functionally relevant immunity, not just incidental antibody presence.

What This Could Mean for Vaccine Design

These are associations drawn from observational data, not a controlled experiment proving that mucosal IgA directly causes protection — the study's authors frame it as a strong predictive correlate rather than definitive proof of a protective mechanism. The implications for vaccine strategy are still worth weighing. Most current RSV vaccines and antibody therapies are designed to boost blood-based IgG, and they've clearly succeeded at preventing severe outcomes like hospitalization. But if mucosal IgA is doing more of the work in blocking infection itself, especially the kind of mild or silent infection that fuels ongoing community transmission, vaccine developers may want to think harder about strategies that stimulate immunity directly at the nasal surface, such as nasally administered vaccines.

This also matters for global equity in RSV research. Because the study was conducted in a high-burden, high-transmission Gambian community rather than a wealthier setting with less frequent RSV exposure, it offers a rare window into how repeated natural exposure shapes immunity in the populations that actually carry most of the world's RSV disease burden. Immune patterns seen in well-resourced countries with lower transmission intensity don't necessarily generalize to places like this, where children and adults may encounter the virus far more often over their lifetimes.

The authors suggest that pairing mucosal and serum antibody measurements could ultimately produce better tools for evaluating vaccine candidates and predicting who remains at risk, particularly for shots aimed at reducing transmission rather than only preventing severe illness. These findings will need replication across other settings and age groups before they reshape vaccine design in practice. Anyone with questions about RSV risk, vaccination, or prevention for themselves or their family should speak with their own healthcare provider.

Source: Nature Communications, DOI: 10.1038/s41467-026-77315-4, based on research by Hodgson, Jarju, de Silva, and colleagues.